Skip to Content

Digoxin Pregnancy and Breastfeeding Warnings

Digoxin is also known as: Cardoxin, Digitek, Digox, Lanoxicaps, Lanoxin

Digoxin Pregnancy Warnings

Animal studies have not been reported. In humans, adverse fetal effects have been reported at doses that produced maternal toxicity. There are no controlled data in human pregnancy. AU TGA pregnancy category A: Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is recommended only if clearly needed and the benefit outweighs the risk. AU TGA pregnancy category: A US FDA pregnancy category: C

See references

Digoxin Breastfeeding Warnings

Caution is recommended. Excreted into human milk: Yes (in small amounts) Comments: This drug has been used without apparent harmful effects in the nursing infant.

This drug is excreted into breast milk in small amounts, and therefore, any amount ingested through breastfeeding would not be expected to cause adverse effects in the nursing infant. If the mother is scheduled to receive this drug intravenously, some experts recommend avoidance of breastfeeding for 2 hours after the dose to lessen the amount received by the infant.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Lanoxin (digoxin)." Glaxo Wellcome, Research Triangle Park, NC.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Lanoxin (digoxin)." Glaxo Wellcome, Research Triangle Park, NC.
  4. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.